Skip to content

Tranexamic Acid

    Brands

    DEA Class; Rx

    Common Brand Names; Lysteda

    • Antifibrinolytic Agents

    Oral and injectable antifibrinolytic
    Used for bleeding prophylaxis during tooth extraction in patients with hemophilia and for treatment of cyclic heavy menstrual bleeding
    May increase the risk of thromboembolic events

    Indicated for the treatment of cyclic heavy menstrual bleeding

    For the treatment of cyclic menorrhagia (heavy menstrual bleeding).

    For the treatment of symptomatic intracranial bleeding occurring within 24 hours after administration of IV alteplase for treatment of acute ischemic stroke.
    For the treatment of active hemorrhage in trauma patients.
    For bleeding prophylaxis, including after ocular trauma (hyphema).

    Hypersensitivity

    Women using combination hormonal contraceptives

    Active thromboembolic disease (eg, DVT, pulmonary embolism, or cerebral thrombosis)

    History of thrombosis or thromboembolism, including retinal vein or artery occlusion

    Intrinsic risk of thrombosis or thromboembolism (eg, thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy)

    Headache (50.4%)

    Nasal and sinus symptoms (25.4%)

    Back pain (20.7%)

    Abdominal pain (19.8%)

    Musculoskeletal pain (11.2%)

    1-10%

    Arthralgia (6.9%)

    Muscle cramps and spasms (5.8%)

    Migraine (6%)

    Anemia (5.6%)

    Fatigue (5.2%)

    Nausea, vomiting, and diarrhea

    Allergic skin reactions

    Anaphylactic shock and anaphylactoid reactions

    Thromboembolic events (eg, DVT, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery and vein obstruction); cases have been associated with concomitant use of combination hormonal contraceptives Impaired color vision and other visual disturbances

    Dizziness

    Increased risk for thrombosis when coadministered with combination oral contraceptive (see Contraindications), Factor IX complex concentrates, anti-inhibitor coagulant concentrates, or oral tretinoin

    Venous and arterial thrombosis or thromboembolism, as well as cases of retinal artery and retinal vein occlusions, have been reported

    Severe allergic reaction reported; anaphylactic shock reported with IV product

    May cause cerebral edema and cerebral infarction in women with subarachnoid hemorrhage

    Ligneous conjunctivitis reported

    Not indicated for use in pregnant women; there are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; tranexamic acid crosses the placenta; animal reproduction studies have not identified adverse developmental outcomes with oral administration of tranexamic acid to pregnant rats at doses up to 4 times the recommended human dose

    Tranexamic acid is present in the mother’s milk at a concentration of about one hundredth of the corresponding serum concentration

    Adults

    3,900 mg/day PO; 40 mg/kg/day IV.

    Geriatric

    3,900 mg/day PO; 40 mg/kg/day IV.

    Adolescents

    3,900 mg/day PO; 40 mg/kg/day IV has been used after tooth extraction in hemophilia patients.

    Children

    12 years: 3,900 mg/day PO; 40 mg/kg/day IV has been used after tooth extraction in hemophilia patients.
    1 to 11 years: Safety and efficacy have not been established for oral dosing; 40 mg/kg/day IV has been used after tooth extraction in hemophilia patients.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Tranexamic acid

    tablet

    • 650mg